What is the role of thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenia (ITP) in adults?

Updated: Nov 30, 2019
  • Author: Perumal Thiagarajan, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print


In a significant proportion of patients with ITP, ineffective platelet production from megakaryocytes plays a major role in causing thrombocytopenia. Stimulation of megakaryopoiesis by exogenous agents improves the platelet count. Two thrombopoietin receptor agonists have been approved for the treatment of chronic refractory ITP: eltrombopag and romiplostim.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!